Indoximod and Provenge Combo Lengthens Time for Prostate Cancer to Progress, Trial Shows

Indoximod and Provenge Combo Lengthens Time for Prostate Cancer to Progress, Trial Shows
A combination of NewLink Genetics‘ immunotherapy indoximod and the cancer vaccine Provenge more than doubled the time it took for an advanced cancer patient’s disease to progress, compared with Provenge alone, according to a Phase 2 clinical trial. The study applied to metastatic castration resistant prostate cancer, or mCRPC. The disease-progression yardstick researchers used was the time

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *